Merck To Pay $688M To Settle Investor Suits Over Vytorin

Law360, New York (February 14, 2013, 12:32 PM EST) -- Merck & Co. said Thursday it will pay $688 million to settle two class actions alleging the drugmaker and subsidiary Schering-Plough hid test results for their anti-cholesterol drug Vytorin from investors, inking what plaintiffs' attorneys called one of the top 25 securities class action settlements ever.

The pharmaceutical company will pay $473 million to settle a Schering-Plough class action and $215 million to settle a Merck class action instituted by investors in New Jersey federal court who said they lost money when the results of a...
To view the full article, register now.